Confronto

Amycretin vs. Efinopegdutide

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Metabolico

N. CAS

nessun dato

2055640-93-0

Peso molecolare

nessun dato

Emivita

nessun dato

115 h

Sequenza

nessun dato

modifiziertes, von Oxyntomodulin abgeleitetes Peptid, konjugiert an ein humanes IgG4-Fragment (Verlängerung der Plasma-Halbwertszeit)

Meccanismo d'azione

Amycretin

Amycretin activates both the GLP-1 and the amylin receptor in a single molecule. Both pathways independently suppress appetite and food intake — the combination is intended to amplify the effect beyond the GLP-1 axis alone.

Efinopegdutide

Efinopegdutide is an oxyntomodulin-derived peptide acting as a dual agonist at the GLP-1 and glucagon receptors with a relative potency of approximately 2:1 (GLP-1 to glucagon). The GLP-1 component mediates glucose-dependent insulin secretion and modulation of satiety; the glucagon component increases energy expenditure and hepatic fat oxidation, which is proposed to contribute to the observed reduction in liver fat. Conjugation to an IgG4 fragment prolongs the half-life and enables weekly administration.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Amycretin	Efinopegdutide
Germania	Non approvato	Non approvato
Stati Uniti	Non approvato	Non approvato

Voci complete

Frequently asked questions

What is the difference between Amycretin and Efinopegdutide?: Amycretin is classified as "Metabolico", while Efinopegdutide is classified as "Metabolico". Amycretin: Amycretin is a unimolecular GLP-1 and amylin receptor agonist from Novo Nordisk — in development both as a once-weekly subcutaneous and a once-daily oral form for obesity and type 2 diabetes. Efinopegdutide: Efinopegdutide (MK-6024, formerly JNJ-64565111 / HM12525A) is a once-weekly dual agonist at the GLP-1 and glucagon receptors, developed by Hanmi and Merck. It has been studied for obesity and notably for metabolic liver disease (MASH/NAFLD); a phase-2 trial showed greater liver-fat reduction than semaglutide. Investigational, not approved. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Amycretin or Efinopegdutide?: The highest available evidence level is "RCT sull'uomo" for Amycretin and "RCT sull'uomo" for Efinopegdutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Amycretin and Efinopegdutide in Germany and the United States?: Germania: Amycretin — Non approvato, Efinopegdutide — Non approvato. Stati Uniti: Amycretin — Non approvato, Efinopegdutide — Non approvato. These are factual summaries with source and review date on the individual pages.

Country

Amycretin

Efinopegdutide

Germania

Non approvato

Stati Uniti

Non approvato

Frequently asked questions

What is the difference between Amycretin and Efinopegdutide?

Amycretin is classified as "Metabolico", while Efinopegdutide is classified as "Metabolico". Amycretin: Amycretin is a unimolecular GLP-1 and amylin receptor agonist from Novo Nordisk — in development both as a once-weekly subcutaneous and a once-daily oral form for obesity and type 2 diabetes. Efinopegdutide: Efinopegdutide (MK-6024, formerly JNJ-64565111 / HM12525A) is a once-weekly dual agonist at the GLP-1 and glucagon receptors, developed by Hanmi and Merck. It has been studied for obesity and notably for metabolic liver disease (MASH/NAFLD); a phase-2 trial showed greater liver-fat reduction than semaglutide. Investigational, not approved. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Amycretin or Efinopegdutide?

The highest available evidence level is "RCT sull'uomo" for Amycretin and "RCT sull'uomo" for Efinopegdutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Amycretin and Efinopegdutide in Germany and the United States?

Germania: Amycretin — Non approvato, Efinopegdutide — Non approvato. Stati Uniti: Amycretin — Non approvato, Efinopegdutide — Non approvato. These are factual summaries with source and review date on the individual pages.